◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › AGIO

Agios Pharm (AGIO) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-12

Agios Pharm (AGIO) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 539 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, AGIO reported $54M in revenue and ($413M) in net income.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.

Interactive charts & full statements → Open the AGIO valuation workbench →

AGIO Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$98M	$54M	$36M	$27M	$14M	$0M	$203M	$118M	$94M	$43M	$70M	$59M	$65M	$26M	$25M	$22M
Gross Profit	$86M	$43M	$32M	$17M	$13M	($19M)	($19M)	$117M	$93M	$43M	$70M	$59M	$65M	$26M	($16M)	$22M
Gross Margin %	87.9%	78.7%	88.6%	64.6%	88.0%	-45345.2%	-9.2%	98.9%	98.5%	100.0%	100.0%	100.0%	100.0%	100.0%	-63.4%	100.0%
Operating Income (EBIT)	($459M)	($472M)	($426M)	($391M)	($389M)	($378M)	($336M)	($426M)	($362M)	($321M)	($201M)	($119M)	($54M)	($39M)	($23M)	($17M)
Operating Margin %	-466.8%	-873.9%	-1166.5%	-1459.5%	-2732.1%	-913854.5%	-165.3%	-361.6%	-384.0%	-745.8%	-287.6%	-200.8%	-82.8%	-152.2%	-91.6%	-76.2%
Net Income	($411M)	($413M)	$674M	($352M)	($232M)	$1.6B	($327M)	($411M)	($346M)	($315M)	($198M)	($118M)	($54M)	($39M)	($20M)	($24M)
Net Margin %	-418.2%	-764.0%	1845.9%	-1312.6%	-1627.8%	3875280.7%	-161.1%	-349.0%	-366.6%	-731.6%	-284.0%	-199.1%	-81.9%	-154.2%	-80.1%	-108.6%
EBITDA	($417M)	($409M)	$724M	($345M)	($223M)	($338M)	($311M)	($395M)	($355M)	($314M)	($195M)	($115M)	($53M)	($37M)	($22M)	($16M)
Earnings Per Share (EPS)	$-7.01	$-7.12	$11.64	$-6.33	$-4.23	$26.55	$-4.74	$-6.86	$-6.03	$-6.75	$-5.07	$-3.15	$-1.59	$-2.56	$-0.86	$-1.01
Shares Outstanding (M)	59M	58M	58M	56M	55M	60M	69M	60M	57M	47M	39M	37M	34M	15M	23M	23M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AGIO Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$45M	$21M	$20M	$13M	$12M	$9M	$11M	$9M
Gross Profit	$42M	$18M	$17M	$10M	$9M	$6M	$9M	$8M
Gross Margin %	93.3%	87.1%	84.2%	76.3%	76.2%	72.9%	88.3%	91.3%
Operating Income (EBIT)	($111M)	($110M)	($122M)	($117M)	($127M)	($107M)	($125M)	($103M)
Operating Margin %	-247.1%	-530.3%	-608.9%	-907.4%	-1020.1%	-1222.0%	-1165.3%	-1146.9%
Net Income	($101M)	($99M)	($108M)	($103M)	($112M)	($89M)	($97M)	$948M
Net Margin %	-225.1%	-477.7%	-541.1%	-803.0%	-899.4%	-1023.2%	-899.6%	10574.7%
EBITDA	($109M)	($98M)	($108M)	($102M)	($111M)	($88M)	($104M)	$1.0B
Earnings Per Share (EPS)	$-1.69	$-1.69	$-1.85	$-1.78	$-1.93	$-1.55	$-1.69	$16.22
Shares Outstanding (M)	59M	59M	58M	58M	58M	57M	57M	58M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AGIO Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($361M)	($373M)	($390M)	($296M)	($309M)	($407M)	($291M)	($371M)	($304M)	($285M)	$39M	($77M)	($59M)	($56M)	($50M)	($15M)
Capital Expenditures (CapEx)	$5M	$4M	$2M	$1M	$5M	$6M	$14M	$12M	$7M	$5M	$10M	$20M	$2M	$1M	$1M	$2M
Free Cash Flow (FCF)	($365M)	($377M)	($392M)	($297M)	($314M)	($413M)	($305M)	($383M)	($311M)	($290M)	$29M	($97M)	($62M)	($58M)	($51M)	($17M)
FCF Margin %	-371.4%	-698.3%	-1072.7%	-1107.5%	-2207.6%	-997515.0%	-150.0%	-324.6%	-329.9%	-673.9%	41.0%	-164.3%	-94.2%	-225.8%	-203.2%	-78.4%
Dividends Paid	—	—	—	—	—	$37M	—	—	—	$0M	$0M	$0M	$0M	$0M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AGIO Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($57M)	($119M)	($96M)	($88M)	($77M)	($111M)	($133M)	($84M)
Capital Expenditures (CapEx)	$1M	$1M	$1M	$2M	$1M	$1M	$1M	$0M
Free Cash Flow (FCF)	($59M)	($120M)	($97M)	($90M)	($78M)	($112M)	($134M)	($85M)
FCF Margin %	-130.8%	-576.9%	-487.5%	-696.5%	-626.2%	-1286.4%	-1250.1%	-944.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AGIO Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$1.1B	$1.3B	$1.7B	$937M	$1.2B	$1.4B	$853M	$891M	$858M	$614M	$619M	$420M	$492M	$201M	$137M	$194M
Cash & Cash Equivalents	$100M	$89M	$76M	$88M	$139M	$203M	$127M	$81M	$805M	$568M	$574M	$376M	$14M	$72M	$91M	$118M
Total Liabilities	$82M	$104M	$122M	$126M	$138M	$146M	$453M	$250M	$171M	$239M	$261M	$75M	$68M	$70M	$93M	$131M
Total Debt (Short + Long-Term)	$19M	$18M	$17M	$15M	$14M	$11M	$7M	$7M	$60M	$126M	$154M	$5M	$14M	$8M	$7M	$19M
Total Shareholders' Equity	$1.0B	$1.2B	$1.5B	$811M	$1.1B	$1.3B	$400M	$641M	$688M	$376M	$359M	$345M	$424M	$131M	$44M	$63M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AGIO viewer.

Other Companies in BIOTECHNOLOGY

RXRX · Recursion Pharmaceuticals Inc — $2 billion
ZBIO · Zenas BioPharma, Inc. Common Stock — $2 billion
VCEL · Vericel Corp Ord — $2 billion
ADMA · ADMA Biologics Inc — $2 billion
MESO · Mesoblast Ltd — $2 billion
RAPP · Rapport Therapeutics, Inc. Common Stock — $2 billion
GHRS · GH Research PLC — $2 billion
COAG · Hemab Therapeutics Holdings, Inc. Common Stock — $2 billion

← AGIL All “A” companies AGIQ →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.